Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Hobbs

Showing results (371-380 of 381) with videos related to

Pageof 39
Sort By:
Proceedings of the National Academy of Sciences of the United States of America|August 23, 2017
Sensitized mutagenesis screen in Factor V Leiden mice identifies thrombosis suppressor lociRandal J Westrick, Kärt Tomberg, Amy E Siebert, et al.
Blood Cancer Journal|May 30, 2023
Daratumumab, carfilzomib, and pomalidomide for the treatment of POEMS syndrome: The Mayo Clinic ExperienceI Vaxman, S K Kumar, F Buadi, et al.
Leukemia|June 17, 2024
Correction: Outcomes among newly diagnosed AL amyloidosis patients with a very high NT-proBNP: implications for trial designI Vaxman, S K Kumar, F Buadi, et al.
Cancer Discovery|May 29, 2014
Vulnerabilities of PTEN-TP53-deficient prostate cancers to compound PARP-PI3K inhibitionEnrique González-Billalabeitia, Nina Seitzer, Su Jung Song, et al.
Leukemia|May 22, 2021
Outcomes among newly diagnosed AL amyloidosis patients with a very high NT-proBNP: implications for trial designI Vaxman, S K Kumar, F Buadi, et al.
Nature Communications|April 8, 2016
Large-scale production of megakaryocytes from human pluripotent stem cells by chemically defined forward programmingThomas Moreau, Amanda L Evans, Louella Vasquez, et al.
Nature Communications|July 29, 2017
Corrigendum: Large-scale production of megakaryocytes from human pluripotent stem cells by chemically defined forward programmingThomas Moreau, Amanda L Evans, Louella Vasquez, et al.
Blood Cancer Journal|December 8, 2021
"Real-life" data of the efficacy and safety of belantamab mafodotin in relapsed multiple myeloma-the Mayo Clinic experienceI Vaxman, J Abeykoon, A Dispenzieri, et al.
Elife|December 10, 2016
Assessing the mechanism and therapeutic potential of modulators of the human Mediator complex-associated protein kinasesPaul A Clarke, Maria-Jesus Ortiz-Ruiz, Robert TePoele, et al.
Nature Genetics|February 28, 2012
Compound inheritance of a low-frequency regulatory SNP and a rare null mutation in exon-junction complex subunit RBM8A causes TAR syndromeCornelis A Albers, Dirk S Paul, Harald Schulze, et al.
Pageof 39

Showing results (371-380 of 381) with videos related to

Sort By:
Pageof 39
Proceedings of the National Academy of Sciences of the United States of America|August 23, 2017
Sensitized mutagenesis screen in Factor V Leiden mice identifies thrombosis suppressor lociRandal J Westrick, Kärt Tomberg, Amy E Siebert, et al.
Blood Cancer Journal|May 30, 2023
Daratumumab, carfilzomib, and pomalidomide for the treatment of POEMS syndrome: The Mayo Clinic ExperienceI Vaxman, S K Kumar, F Buadi, et al.
Leukemia|June 17, 2024
Correction: Outcomes among newly diagnosed AL amyloidosis patients with a very high NT-proBNP: implications for trial designI Vaxman, S K Kumar, F Buadi, et al.
Cancer Discovery|May 29, 2014
Vulnerabilities of PTEN-TP53-deficient prostate cancers to compound PARP-PI3K inhibitionEnrique González-Billalabeitia, Nina Seitzer, Su Jung Song, et al.
Leukemia|May 22, 2021
Outcomes among newly diagnosed AL amyloidosis patients with a very high NT-proBNP: implications for trial designI Vaxman, S K Kumar, F Buadi, et al.
Nature Communications|April 8, 2016
Large-scale production of megakaryocytes from human pluripotent stem cells by chemically defined forward programmingThomas Moreau, Amanda L Evans, Louella Vasquez, et al.
Nature Communications|July 29, 2017
Corrigendum: Large-scale production of megakaryocytes from human pluripotent stem cells by chemically defined forward programmingThomas Moreau, Amanda L Evans, Louella Vasquez, et al.
Blood Cancer Journal|December 8, 2021
"Real-life" data of the efficacy and safety of belantamab mafodotin in relapsed multiple myeloma-the Mayo Clinic experienceI Vaxman, J Abeykoon, A Dispenzieri, et al.
Elife|December 10, 2016
Assessing the mechanism and therapeutic potential of modulators of the human Mediator complex-associated protein kinasesPaul A Clarke, Maria-Jesus Ortiz-Ruiz, Robert TePoele, et al.
Nature Genetics|February 28, 2012
Compound inheritance of a low-frequency regulatory SNP and a rare null mutation in exon-junction complex subunit RBM8A causes TAR syndromeCornelis A Albers, Dirk S Paul, Harald Schulze, et al.
Pageof 39